This information is current as Autoimmune Encephalomyelitis Onset Ameliorates Experimental of Encephalitogenic T Cells or After Disease Blockade of CD 28 During In Vitro Activation

[1]  E. Lavi,et al.  Experimental autoimmune meningitis: a novel neurological disease in CD28-deficient mice. , 1999, Clinical immunology.

[2]  Andreas Hutloff,et al.  ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 , 1999, Nature.

[3]  P. Blair,et al.  Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction , 1998, The Journal of Immunology.

[4]  Nitin J. Karandikar,et al.  Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE , 1997, Journal of Neuroimmunology.

[5]  G. Chaudhri,et al.  Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system , 1997, European journal of immunology.

[6]  K. Frei,et al.  Tumor Necrosis Factor (cid:2) and Lymphotoxin (cid:2) Are Not Required for Induction of Acute Experimental Autoimmune Encephalomyelitis , 2002 .

[7]  Yan Wu,et al.  CTLA-4–B7 Interaction Is Sufficient to Costimulate T Cell Clonal Expansion , 1997, The Journal of experimental medicine.

[8]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[9]  C. June,et al.  Mitogenic stimulation of T cells reveals differing contributions for B7‐1 (CD80) and B7‐2 (CD86) costimulation , 1997, Immunology.

[10]  G. Mills,et al.  CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. , 1997, Journal of immunology.

[11]  J. Allison,et al.  Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis , 1997, Journal of Neuroimmunology.

[12]  H. Offner,et al.  Myelin basic protein-specific and TCR V beta 8.2-specific T-cell lines from TCR V beta 8.2 transgenic mice utilize the same V alpha and V beta genes: specificity associated with the V alpha CDR3-J alpha region. , 1997, Journal of neuroscience research.

[13]  A. Vandenbark,et al.  Myelin basic crotein‐specific and TCR Vβ8.2‐Specific T‐cell lines from TCR Vβ8.2 transgenic mice utilize the same Vα and Vβ genes: specificity associated with the Vα CDR3‐Jα region , 1997 .

[14]  S. Miller,et al.  Epitope spreading , 1996, Current Opinion in Immunology.

[15]  M. Jensen,et al.  Global inhibition of IL-2 and IFN-gamma secreting T cells precedes recovery from acute monophasic experimental autoimmune encephalomyelitis. , 1996, Journal of autoimmunity.

[16]  E. Fuchs,et al.  CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. , 1996, Immunity.

[17]  C. June,et al.  CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[18]  T. Mak,et al.  Induction of autoimmunity in the absence of CD28 costimulation. , 1996, Journal of immunology.

[19]  Nitin J. Karandikar,et al.  CTLA-4: a negative regulator of autoimmune disease , 1996, The Journal of experimental medicine.

[20]  M. W. Flye,et al.  Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[21]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[22]  D. Harlan,et al.  Protection against lethal toxic shock by targeted disruption of the CD28 gene , 1996, The Journal of experimental medicine.

[23]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[24]  T. Sullivan,et al.  Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. , 1996, International immunology.

[25]  C. June,et al.  Opposing effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on experimental allergic encephalomyelitis , 1996, Journal of Neuroimmunology.

[26]  Nitin J. Karandikar,et al.  Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. , 1995, Immunity.

[27]  C. June,et al.  Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. , 1995, The Journal of clinical investigation.

[28]  R. Karr,et al.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.

[29]  D. Loh,et al.  Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. , 1995, Journal of immunology.

[30]  R. Karr,et al.  Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. , 1995, The Journal of clinical investigation.

[31]  Laurie H Glimcher,et al.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.

[32]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[33]  P. Albert,et al.  Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. , 1995, Journal of immunology.

[34]  C. June,et al.  Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation. , 1995, Journal of immunology.

[35]  J. Banchereau,et al.  B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells , 1994, The Journal of experimental medicine.

[36]  P. Linsley,et al.  Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.

[37]  J. Bluestone,et al.  The B7 and CD28 receptor families. , 1994, Immunology today.

[38]  W. Paul,et al.  CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3 , 1994, The Journal of experimental medicine.

[39]  J. Gribben,et al.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production , 1993, The Journal of experimental medicine.

[40]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[41]  K P Lee,et al.  Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.

[42]  J. Gribben,et al.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Hood,et al.  Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity , 1993, Cell.

[44]  P. Linsley,et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.

[45]  J. Allison,et al.  Identification and distribution of the costimulatory receptor CD28 in the mouse. , 1992, Journal of immunology.

[46]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[47]  R. Clark,et al.  An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis , 1990, The Journal of experimental medicine.

[48]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[49]  C. Thompson,et al.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[50]  C. Pettinelli,et al.  Encephalitogenic activity of guinea pig myelin basic protein in the SJL mouse. , 1982, Journal of immunology.

[51]  R. Hohlfeld.  Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? , 1996, Multiple sclerosis.

[52]  P. Linsley,et al.  Role of the CD28 receptor in T-cell activation. , 1990, Immunology today.

[53]  R. Martenson,et al.  Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. , 1972, Preparative biochemistry.